Aytu's EXXUA Launch Finally Has Arithmetic — and the Numbers Are About Reps, Not Just Scripts
A micro-cap antidepressant launch doubles prescriptions-per-rep while flipping the whole company to positive adjusted EBITDA
AYTU · Earnings Call · 2026-09-22
EXXUA stops being a promise
Aytu BioPharma is a roughly $23 million-market-cap specialty pharma that has spent years shrinking toward a single bet: EXXUA, an atypical antidepressant for major depressive disorder built on a 5-HT1A receptor agonist mechanism. Fiscal Q4 2026, ended June 30, was its first full commercial quarter — and for the first time the launch has arithmetic attached. EXXUA revenue climbed to $3.9 million from $2.4 million in the prior quarter; total company revenue was $16.1 million, up 6% year over year and up from $12.4 million sequentially; and consolidated adjusted EBITDA flipped to a positive $0.5 million from negative $2.8 million just three months earlier. Joshua Disbrow frames the asset plainly: “It's the first and only selective serotonin 5-HT1A receptor agonist approved by the FDA for the treatment of major depressive disorder in adults. Its novel mechanism and differentiated tolerability profile address an important need in a category where many patients struggle to find a treatment that works well for them and that they can stay on.” — Joshua Disbrow, Chief Executive Officer · 2026-09-22 The funnel is filling: total prescriptions ran 3,323 in the June quarter versus 1,398 in March, with a monthly cadence of 973, 1,089 and 1,261 in April through June, then 1,377 in July and 1,408 in August. Management counts nearly 1,200 unique prescribers and roughly 2,500 unique patients to date — a prescriber base still mostly one-and-two-patient deep, which is precisely the deepening opportunity. The striking part is the week ending September 4, when Aytu printed 394 prescriptions, a step-change above the July–August plateau, even though much of the field force had not yet ramped.The rep purge is the real signal
The most interesting disclosure isn't revenue at all — it's that management deliberately culled its own sales force mid-launch and the productivity math improved anyway. Sales specialists went from 43 in March to a low of 32 in July, back to roughly 42 now. Yet monthly prescriptions rose 81% over that arc, and prescriptions per sales rep went from about 18 to roughly 43. Disbrow's point is that breadth, not a top-heavy handful of territories, drives the number: 24 territories, about 60% of the field, generate 70% of actual prescriptions. That is a healthier distribution than a typical launch, and it supports the “methodical, ROI-gated” language Aytu has repeated all year. The run-rate arithmetic is the bull case in miniature: roughly 45 territories at 15 scripts per rep per week dollars out to a $26 million annual run rate, 20 per week to ~$35 million, and 30 per week to over $50 million. Those aren't first-line patients — payers require prior SSRI/SNRI failures — but the funnel is enormous. On ramp timing he is candid: “6 to 9 months realistically is a good timeframe to really think of somebody as sort of adequately tooled for the job. And if you look at really sort of a breakeven analysis, you would look at something closer to 9 or 12 months.” — Joshua Disbrow, Chief Executive Officer · 2026-09-22 That means the September spike is happening with a partially trained team — a favorable read-through for fiscal 2027. Access is the quiet tailwind. The approval rate on prior authorizations is running high: “the approval rates for prior authorizations are quite high. If you look at the success we're having with claims that are submitted sort of through the program, it's in the neighborhood of 70%.” — Joshua Disbrow, Chief Executive Officer · 2026-09-22 Executive tone on contracting hasn't budged in a year — Aytu refuses to sign step function-promising payer deals that could reset government best-price. Disbrow again: “we're at the point of not proactively contracting same on both sides, government and commercial. It doesn't do us any good to contract on the government side and pay large supplemental rebates when states in one way, shape or form will cover this.” — Joshua Disbrow, Chief Executive Officer · 2026-09-22 Government now runs north of 20–25% of the mix, versus the 35–40% analogs achieve, so payer mix is a second lever that improves economics without a single new contract.Cash, guidance, and what the tape says
The legacy business funds all of this. ADHD revenue was $10.4 million (down from $13.1 million a year ago but up from $9.1 million sequentially on better gross-to-net), pediatrics $1.8 million. The balance sheet improved materially: cash of $26.3 million held roughly flat sequentially while the revolver was paid down and the fixed payment arrangements were retired. Note the supplied fundamentals lag the call by a quarter — the last filed quarter shows total revenue of $12 million, down 33% year over year and a 61.2% gross margin, dragged by a one-time inventory write-down the June quarter reverses. Balance-sheet quality is the swing factor here: effective net cash of $15 million is up sharply year over year, and liabilities at 75.8% of assets remains the principal risk for a company funding a launch out of its own pocket.Two things temper the enthusiasm. First, the stock is doing nothing: shares are flat over 90 days (-0.9%) and sit about 5% below their August 11 intraday peak near $2.40, so the equity market is not yet voting on this inflection. Second, the recurring theme that nothing scales without cash — flagged in February, when Disbrow said “the primary trigger with the board approval will be cash flow supporting it” — Josh Disbrow, Chief Executive Officer · 2026-02-03 — still caps how fast the rep count can grow. On the other side, Teva has not launched its Cotempla generic despite a July 1 opening, an unmodeled upside to the ADHD base case. Net: this isn't a sector story and it rides none of the global tariff/AI-datacenter themes. It's a company-unique launch inflection with hard field metrics, a self-funded P&L and a guidance line that just got a date. For a $23 million company, that is a genuinely new piece of information.We expect lower adjusted EBITDA and operating cash flow in the first half of fiscal 2027 than in the second half... Based on our current plans taken together, we expect the 6-month period ending June 30, 2027, to generate positive adjusted EBITDA.